Stay updated with breaking news from Daniela Camardo. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Athersys (NASDAQ: ATHX) recently received a number of ratings updates from brokerages and research firms: 6/8/2022 – Athersys was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Athersys, Inc., a late stage biotechnology company, focuses on the research and development activities in the field of […]
Athersys (NASDAQ:ATHX – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Wednesday, Zacks.com reports. According to Zacks, “Athersys, Inc., a late stage biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs […]
Athersys (NASDAQ:ATHX – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Wednesday, Zacks.com reports. According to Zacks, “Athersys, Inc., a late stage biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs […]
On 04/11/2022, Athersys shares spiked after a long downward slide, soon they were back on the skids. Read more about ATHX stock here.
Zacks Investment Research downgraded shares of Athersys (NASDAQ:ATHX – Get Rating) from a buy rating to a hold rating in a report published on Tuesday, Zacks.com reports. According to Zacks, “Athersys, Inc., a late stage biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are […]